secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2022-03-15T23:59:59+00:00
Accession:  0001104659-22-033991
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Therapeutics enters $30M equity line with Lincoln Park Capital; names Tyler Zeronda CFO
--------------------------------------------------------------------------------

- Up to $30M of common stock can be sold to Lincoln Park over 36 months; 1,667,593 commitment shares issued.
- Regular purchases up to 200,000 shares/day (increased to 400,000 if closing price >= $1.00); pricing at discount to market.
- Exchange cap of 11,227,637 shares (19.99% of outstanding) unless stockholder approval or avg price >= $0.545.
- Tyler Zeronda appointed CFO and Treasurer effective March 14, 2022; annual base salary $340,000 with 40% target bonus.
- Proceeds from equity line expected to be used for working capital and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922033991/0001104659-22-033991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922033991/tm229153d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-033991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer